ME Therapeutics Holdings Inc.
METXF
$2.95
$0.000.00%
OTC PK
| 02/28/2025 | 11/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -52.89% | -9.40% | |||
| Depreciation & Amortization | 88.16% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.29% | -5.31% | |||
| Operating Income | 36.29% | 5.31% | |||
| Income Before Tax | 36.24% | 3.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.24% | 3.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.24% | 3.86% | |||
| EBIT | 36.29% | 5.31% | |||
| EBITDA | 38.03% | 5.61% | |||
| EPS Basic | 40.23% | 3.33% | |||
| Normalized Basic EPS | 38.89% | 5.26% | |||
| EPS Diluted | 19.54% | 3.33% | |||
| Normalized Diluted EPS | 38.89% | 5.26% | |||
| Average Basic Shares Outstanding | 6.53% | -0.02% | |||
| Average Diluted Shares Outstanding | 6.53% | -0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||